Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum
Abstract Background Alzheimer’s disease is characterized by an abnormal increase of phosphorylated tau (pTau) species in the CSF. It has been suggested that emergence of different pTau forms may parallel disease progression. Therefore, targeting multiple specific pTau forms may allow for a deeper un...
Main Authors: | Johan Gobom, Andréa L. Benedet, Niklas Mattsson-Carlgren, Laia Montoliu-Gaya, Nina Schultz, Nicholas J. Ashton, Shorena Janelidze, Stijn Servaes, Mathias Sauer, Tharick A. Pascoal, Thomas K. Karikari, Juan Lantero-Rodriguez, Gunnar Brinkmalm, Henrik Zetterberg, Oskar Hansson, Pedro Rosa-Neto, Kaj Blennow |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-12-01
|
Series: | Molecular Neurodegeneration |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13024-022-00586-0 |
Similar Items
-
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
by: Claudia Cicognola, et al.
Published: (2021-03-01) -
Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease
by: Juan Lantero-Rodriguez, et al.
Published: (2024-02-01) -
Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology
by: Joseph Therriault, et al.
Published: (2024-01-01) -
Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease
by: Johanna Nilsson, et al.
Published: (2022-06-01) -
Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
by: Niklas Mattsson-Carlgren, et al.
Published: (2021-01-01)